Clinical trial
A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo
NCT00224107 · Watson Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00224107 |
|---|---|
| Title | A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia |
| Lead sponsor | Watson Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Benign Prostatic Hyperplasia (BPH) |
| Intervention type | Drug, Other |
| Interventions | Silodosin, Placebo |
| Enrollment | 461 |
| Start date | May 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Jul 12, 2011 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: